Immodulon Therapeutics, a clinical stage immuno-oncology company based in Uxbridge, UK, announced a partnership with Biodesix, a Colorado, US-based company providing diagnostic solutions for companies developing cancer treatments.
The agreement will see Immodulon adopt the Diagnostic Cortex platform, created by Biodesix, aiming to accelerate the clinical development of IMM-101, an investigational treatment for advanced pancreatic cancer.
Biodesix Diagnostic Cortex utilizes machine learning to process data found in the circulating proteome and genome and designs tests that support treatment decisions, including patient selection for immunotherapies.
The partners will work on the analysis of the circulating proteome of advanced pancreatic cancer patients treated with IMM-101, using Diagnostic Cortex’ function to identify biomarker patterns through artificial intelligence (AI), enabling personalized therapy selection.
According to results from Immodulon’s clinical trials, metastatic pancreatic cancer patients receiving IMM-101 and gemcitabine benefitted from a 59% increase in median overall survival compared to those receiving gemcitabine alone.
“By utilizing the Biodesix Diagnostic Cortex in identifying blood-based proteomic biomarkers, we hope to facilitate selection of those patients most likely to respond to IMM-101,” Immodulon’s CEO, Jaap Kampinga, said in a statement.
“This could improve the efficiency of treatment and patient care, and accelerate our clinical trial programmes,” he added.
On his side, David Brunel, CEO of Biodesix stated that Diagnostic Cortex is ‘well suited’ to advancing the clinical research for IMM-101.